Spero Therapeutics (NASDAQ:SPRO) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a hold rating to a strong-buy rating in a research report released on Sunday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Spero Therapeutics Stock Performance

Shares of SPRO stock opened at $2.33 on Friday. Spero Therapeutics has a twelve month low of $0.51 and a twelve month high of $3.22. The stock has a fifty day simple moving average of $2.35 and a two-hundred day simple moving average of $2.31. The stock has a market capitalization of $131.27 million, a price-to-earnings ratio of 19.42 and a beta of 1.45.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, March 26th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.73. The firm had revenue of $41.30 million for the quarter, compared to analyst estimates of $26.00 million. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%. Research analysts predict that Spero Therapeutics will post -1.2 EPS for the current fiscal year.

Insider Activity

In other news, insider Esther Rajavelu sold 87,917 shares of the business’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.36, for a total value of $207,484.12. Following the completion of the transaction, the insider directly owned 1,012,091 shares of the company’s stock, valued at approximately $2,388,534.76. The trade was a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. GSK plc bought a new position in Spero Therapeutics in the fourth quarter worth about $21,414,000. Vanguard Group Inc. boosted its holdings in shares of Spero Therapeutics by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock valued at $3,741,000 after buying an additional 39,474 shares in the last quarter. State Street Corp boosted its holdings in shares of Spero Therapeutics by 10.1% in the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after buying an additional 19,200 shares in the last quarter. Ionic Capital Management LLC grew its position in shares of Spero Therapeutics by 39.2% in the 3rd quarter. Ionic Capital Management LLC now owns 208,725 shares of the company’s stock worth $392,000 after buying an additional 58,725 shares during the last quarter. Finally, Intrepid Family Office LLC grew its position in shares of Spero Therapeutics by 50.0% in the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock worth $384,000 after buying an additional 55,000 shares during the last quarter. Institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.